Francois Brisebois
Stock Analyst at Oppenheimer
(1.99)
# 1,611
Out of 4,412 analysts
60
Total ratings
37.29%
Success rate
-8.07%
Average return
Main Sectors:
24 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALDX Aldeyra Therapeutics | Upgrades: Outperform | $10 | $3.93 | +154.45% | 1 | Apr 3, 2024 | |
| KALA Kala Pharmaceuticals | Reiterates: Outperform | $15 | $6.30 | +138.10% | 1 | Apr 1, 2024 | |
| DRRX DURECT | Reiterates: Outperform | $5 | $0.93 | +436.88% | 3 | Apr 1, 2024 | |
| ACHV Achieve Life Sciences | Reiterates: Outperform | $18 | $4.61 | +290.46% | 4 | Apr 1, 2024 | |
| DYN Dyne Therapeutics | Reiterates: Outperform | $47 | $24.73 | +90.05% | 3 | Mar 26, 2024 | |
| DMAC DiaMedica Therapeutics | Reiterates: Outperform | $7 → $6 | $2.57 | +133.46% | 4 | Mar 21, 2024 | |
| AVDL Avadel Pharmaceuticals | Maintains: Outperform | $27 → $29 | $17.81 | +62.83% | 7 | Mar 5, 2024 | |
| TARS Tarsus Pharmaceuticals | Reiterates: Outperform | $55 → $59 | $32.04 | +84.14% | 3 | Feb 28, 2024 | |
| CYBN Cybin | Reiterates: Outperform | $4 | $0.35 | +1,042.86% | 2 | Aug 30, 2023 | |
| MDWD MediWound | Maintains: Outperform | $63 → $36 | $18.24 | +97.37% | 4 | Aug 17, 2023 | |
| SLP Simulations Plus | Reiterates: Outperform | $67 | $44.69 | +49.92% | 4 | Jul 7, 2023 | |
| HRMY Harmony Biosciences Holdings | Reiterates: Outperform | $69 | $29.32 | +135.33% | 4 | May 26, 2023 | |
| MNMD Mind Medicine (MindMed) | Reiterates: Outperform | $22 | $8.52 | +158.22% | 2 | Apr 14, 2023 | |
| ICAD iCAD, Inc. | Maintains: Outperform | $5 → $4 | $1.47 | +172.11% | 3 | Apr 4, 2023 | |
| PCSA Processa Pharmaceuticals | Maintains: Outperform | $100 → $60 | $2.15 | +2,690.70% | 3 | Apr 3, 2023 | |
| BNGO Bionano Genomics | Maintains: Outperform | $120 → $90 | $0.79 | +11,348.93% | 2 | Feb 6, 2023 | |
| SNSE Sensei Biotherapeutics | Upgrades: Outperform | $5 | $1.02 | +390.20% | 1 | Oct 3, 2022 | |
| AQST Aquestive Therapeutics | Initiates: Outperform | $8.5 | $4.07 | +108.85% | 1 | Sep 7, 2022 | |
| SERA Sera Prognostics | Maintains: Outperform | $17 → $11 | $10.75 | +2.33% | 2 | Aug 29, 2022 | |
| DMTK DermTech | Maintains: Outperform | $48 → $23 | $0.60 | +3,713.63% | 2 | Aug 17, 2022 | |
| MDXH MDxHealth | Assumes: Outperform | $18 | $2.47 | +628.74% | 1 | Jul 18, 2022 | |
| CMPS COMPASS Pathways | Initiates: Outperform | n/a | $7.94 | - | 1 | Oct 29, 2021 | |
| SVRA Savara | Initiates: Outperform | n/a | $4.41 | - | 1 | Mar 15, 2021 | |
| GLMD Galmed Pharmaceuticals | Initiates: Buy | n/a | $0.39 | - | 1 | Feb 4, 2020 |
Aldeyra Therapeutics
Apr 3, 2024
Upgrades: Outperform
Price Target: $10
Current: $3.93
Upside: +154.45%
Kala Pharmaceuticals
Apr 1, 2024
Reiterates: Outperform
Price Target: $15
Current: $6.30
Upside: +138.10%
DURECT
Apr 1, 2024
Reiterates: Outperform
Price Target: $5
Current: $0.93
Upside: +436.88%
Achieve Life Sciences
Apr 1, 2024
Reiterates: Outperform
Price Target: $18
Current: $4.61
Upside: +290.46%
Dyne Therapeutics
Mar 26, 2024
Reiterates: Outperform
Price Target: $47
Current: $24.73
Upside: +90.05%
DiaMedica Therapeutics
Mar 21, 2024
Reiterates: Outperform
Price Target: $7 → $6
Current: $2.57
Upside: +133.46%
Avadel Pharmaceuticals
Mar 5, 2024
Maintains: Outperform
Price Target: $27 → $29
Current: $17.81
Upside: +62.83%
Tarsus Pharmaceuticals
Feb 28, 2024
Reiterates: Outperform
Price Target: $55 → $59
Current: $32.04
Upside: +84.14%
Cybin
Aug 30, 2023
Reiterates: Outperform
Price Target: $4
Current: $0.35
Upside: +1,042.86%
MediWound
Aug 17, 2023
Maintains: Outperform
Price Target: $63 → $36
Current: $18.24
Upside: +97.37%
Simulations Plus
Jul 7, 2023
Reiterates: Outperform
Price Target: $67
Current: $44.69
Upside: +49.92%
Harmony Biosciences Holdings
May 26, 2023
Reiterates: Outperform
Price Target: $69
Current: $29.32
Upside: +135.33%
Mind Medicine (MindMed)
Apr 14, 2023
Reiterates: Outperform
Price Target: $22
Current: $8.52
Upside: +158.22%
iCAD, Inc.
Apr 4, 2023
Maintains: Outperform
Price Target: $5 → $4
Current: $1.47
Upside: +172.11%
Processa Pharmaceuticals
Apr 3, 2023
Maintains: Outperform
Price Target: $100 → $60
Current: $2.15
Upside: +2,690.70%
Bionano Genomics
Feb 6, 2023
Maintains: Outperform
Price Target: $120 → $90
Current: $0.79
Upside: +11,348.93%
Sensei Biotherapeutics
Oct 3, 2022
Upgrades: Outperform
Price Target: $5
Current: $1.02
Upside: +390.20%
Aquestive Therapeutics
Sep 7, 2022
Initiates: Outperform
Price Target: $8.5
Current: $4.07
Upside: +108.85%
Sera Prognostics
Aug 29, 2022
Maintains: Outperform
Price Target: $17 → $11
Current: $10.75
Upside: +2.33%
DermTech
Aug 17, 2022
Maintains: Outperform
Price Target: $48 → $23
Current: $0.60
Upside: +3,713.63%
MDxHealth
Jul 18, 2022
Assumes: Outperform
Price Target: $18
Current: $2.47
Upside: +628.74%
COMPASS Pathways
Oct 29, 2021
Initiates: Outperform
Price Target: n/a
Current: $7.94
Upside: -
Savara
Mar 15, 2021
Initiates: Outperform
Price Target: n/a
Current: $4.41
Upside: -
Galmed Pharmaceuticals
Feb 4, 2020
Initiates: Buy
Price Target: n/a
Current: $0.39
Upside: -